Cellular Biomedicine Group, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cellular Biomedicine Group, Inc.
AstraZeneca Takes Personalized Approach To Cell Therapy With Neogene Buy
The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.
Finance Watch: Morningside Launches Adiso With More Than $60m In Early Funding
Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations.
Finance Watch: Exo Raises $78m To Advance Exosite-Targeting Small Molecules
Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.
ASH 2020: Novel CAR-T Approaches Chase BCMA-Targeting Frontrunners
BMS/bluebird and Janssen/Legend have the leading BCMA-targeting CAR-T therapies for multiple myeloma but Poseida, Allogene, CARsgen, Gracell and CBMG are emerging with novel approaches.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Agreen Biotech Co. Ltd. China
- CBMG Holdings
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.